共 158 条
[1]
Goff DC(2005)Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists J Clin Psychiatry 66 183-194
[2]
Cather C(2010)Schizophrenia patient outcomes research T. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009 Schizophr Bull 36 94-103
[3]
Evins AE(2013)Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet 382 951-962
[4]
Henderson DC(2005)Atypicality of atypical antipsychotics Prim Care Companion J Clin Psychiatry 7 268-274
[5]
Freudenreich O(2006)A review of atypical antipsychotic drugs versus conventional medication in schizophrenia Expert Opin Pharmacother 7 1739-1748
[6]
Copeland PM(2008)Atypical antipsychotics: sedation versus efficacy J Clin Psychiatry 69 18-31
[7]
Kreyenbuhl J(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-218
[8]
Buchanan RW(2006)Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia J Clin Psychiatry 67 3-8
[9]
Dickerson FB(2010)Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile J Pharmacol Exp Ther 333 328-340
[10]
Dixon LB(2011)Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents Neurochem Int 59 925-935